170 related articles for article (PubMed ID: 31371315)
1. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.
Binkley E; Triozzi PL; Rybicki L; Achberger S; Aldrich W; Singh A
Br J Ophthalmol; 2020 Apr; 104(4):524-528. PubMed ID: 31371315
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES
Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725
[TBL] [Abstract][Full Text] [Related]
3. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
4. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Garbe C; Radny P; Linse R; Dummer R; Gutzmer R; Ulrich J; Stadler R; Weichenthal M; Eigentler T; Ellwanger U; Hauschild A
Ann Oncol; 2008 Jun; 19(6):1195-201. PubMed ID: 18281266
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
7. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
8. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].
Richtig E; Langmann G; Schlemmer G; Müllner K; Papaefthymiou G; Bergthaler P; Smolle J
Ophthalmologe; 2006 Jun; 103(6):506-11. PubMed ID: 16763868
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
13. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB; Legha SS; Gonzalez R; Anderson CM; Johnson MM; Liu P; Papadopoulos NE; Eton O; Plager C; Buzaid AC; Prieto VG; Hwu WJ; Frost AM; Alvarado G; Hwu P; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Benjamin RS; Bedikian AY
Melanoma Res; 2009 Feb; 19(1):42-9. PubMed ID: 19430405
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Young AM; Marsden J; Goodman A; Burton A; Dunn JA
Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
[TBL] [Abstract][Full Text] [Related]
18. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
20. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]